IV Iron Therapy Reduced Pregnancy Transfusion Risk

Pregnant patients receiving intravenous iron experienced fewer blood transfusions and improved iron levels compared to oral treatments.

Updated on Sept. 29, 2026 in Pregnancy

Flat opaque gouache-painted editorial illustration of a glass beaker and metal rod, representing maternal health research. — A meta-analysis of 29 clinical trials shows that intravenous iron therapy reduces the need for blood transfusions among pregnant patients. AI Illustration. Upload story photo >

Live Poll

Do you prioritize clinical effectiveness statistics when deciding between different medical treatment options?

A meta-analysis of 29 randomized clinical trials involving 11,771 patients found that intravenous iron therapy significantly lowered the need for blood transfusions during delivery. The findings suggest improved outcomes for pregnant individuals managing iron deficiency anemia.

Why it matters

Reducing the need for blood transfusions during delivery is a key goal in obstetric care, as these procedures carry inherent risks and require additional medical resources. This research provides evidence that intravenous iron may be a more effective strategy for improving maternal and fetal iron status.

A meta-analysis of 29 randomized clinical trials including 11,771 patients showed that intravenous iron, primarily iron sucrose, reduced blood transfusion rates by 37% compared to oral ferrous sulfate. Maternal and neonatal ferritin levels were also notably higher in the intravenous group.

The players

JAMA Network Open

A peer-reviewed, open-access medical journal that publishes original research across all health disciplines.

The details

Intravenous iron works by bypassing the gastrointestinal tract to deliver iron directly into the bloodstream, where it is more readily available for hemoglobin production. In contrast, oral iron absorption is often limited by gastrointestinal side effects and regulation by hepcidin, a hormone that blocks iron uptake. By providing a more efficient, direct infusion, this method allows for a more rapid increase in maternal hemoglobin and ferritin stores by the time of delivery.

February 2018 marked the beginning of the study database search.
The meta-analysis incorporated data from studies completed as early as 2019.
The comprehensive search of clinical trial databases concluded in May 2025.
Findings were officially published in JAMA Network Open on September 23, 2026.

Health Landscape

For decades, oral iron supplementation has been the standard of care for pregnancy-related anemia despite frequent gastrointestinal side effects. This meta-analysis shifts the evidence base toward prioritizing intravenous administration to improve outcomes for high-risk patients.

If you are managing iron deficiency anemia during pregnancy, it is worth discussing with your obstetrician whether intravenous iron may be appropriate for your specific needs. Ask your doctor how your current hemoglobin levels compare to the thresholds where intravenous therapy has shown the most benefit.

The takeaway

Intravenous iron therapy appears to be a safer and more effective alternative to oral supplements for reducing transfusion needs in pregnant patients with iron deficiency. Patients should prioritize regular hemoglobin monitoring and consult their physician to evaluate the best iron supplementation strategy.